Abstract
BackgroundIguratimod (IGU) is a small-molecule antirheumatic drug that was approved in Japan in September 2012. IGU suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6, IL-8, and monocyte chemoattractant protein 1...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have